In Q1 Public Biopharmas Shift Fundraising Into Overdrive
ATLANTA, April 8, 2013 /PRNewswire-USNewswire/ -- Biotech companies generated $5 billion in the first quarter of 2013, just 3% less than the $5.15 billion raised in the first quarter last year. The heavy lifting for the period was carried out by public companies, which were responsible for 65% of the total, according to BioWorld Today, the daily biopharmaceutical news source.
The $3.25 billion raised by these public companies was 33% higher than the $2.5 billion total raised in the same period of 2012. The amount included almost $3 billion in follow-on financings with public companies seizing the opportunity in a favorable investor climate to sell shares at or near their prevailing market value with little to no price discount.
It has been a great quarter for public biotech companies as the sector continued to remain hot with investors, according to Peter Winter, editor of BioWorld Insight, the analytical companion to BioWorld Today. Large biotech companies, with market caps greater than $1 billion, collectively saw their share prices jump by an average of 21.5% in the first quarter.That performance almost doubled the Dow Jones Industrial average, which hit a new historical high and closed the quarter up 11.25%. "A steady flow of positive news from elite biotech companies, including product approvals and strong financial reports, have kept investors engaged. The sector's momentum, which started early last year, shows no signs of slowing down," said Winter. There is already some evidence that this is starting to happen with the Nasdaq Biotechnology Index (NBI), which includes a broad range of large and smaller companies, jumping 16% in the first quarter. The performance of NBI was also mirrored by the BioWorld Stock Report, which recorded an average share price change for the 231 public biotechnology companies tracked by the report at 15.6%. Editor's note: This is an excerpt from today's top BioWorld story. Read the complete article here: https://www.bioworld.com/ BioWorld Today, and its analytical companion, BioWorld Insight, are the biopharmaceutical industry's most respected news sources and have been for more than two decades. All of that information is now leveraged in BioWorld Data, business intelligence for biopharmaceutical executives. Call for details (800) 477-6307. Contact: Lynn Yoffee404-262-5408 www.bioworld.com SOURCE BioWorld
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV